Abstract 2510
Background
Hand-foot syndrome (HFS) related to new targeted therapies is a common cutaneous toxicity, with potentially serious impacts on the patient QoL. Previous reports indicate that the incidence of HFS was about 30% in apatinib monotherapy for NSCLC. HFS was also reported to be associated with immunotherapy. We conducted a phase II clinical trial on apatinib combined with anti-PD-1 antibody SHR-1210 for advanced NSCLC (No. CTR20170090). Whether the combined therapy leads to a dramatic increase in the incidence of HFS remains uncertain. There are a variety of scales to evaluate the patients’ QoL, but the specific scale for patients with HFS needs further verification.
Methods
Multiply questionnaires including the HFS-specific QoL questionnaire (HFS-14), Dermatology Life Quality Index (DLQI), Skindex-16 and short-form 12 health-related questionnaire (SF-12) were developed to measure the effect of HFS on daily activities. The HFS clinical grade was based on NCI-CTCAE, v3.0.
Results
The validation study included 26 patients, of 21 (80%) developed HFS of varying grades, with 8 (31%) of grade 1, 7 (27%) of grade 2 and 6 (23%) of grade 3. 52% of patients declared involving one limb, and the rest patients developed HFS in both the hands and feet. The mean time to occurring HFS was 30 ± 64 days. In patients with various grades of HFS, the mean HFS-14 and DLQI scores were significantly higher with higher HFS grades, whereas the Skindex-16 and SF-12 scores did not differ. Four kinds of scales analysis also showed significant differences according to the degree of limb involvement, where the scores were significantly higher in patients having both hands and feet severely involved than in those having severe involvement of either only the hands or feet. When in patients with grade 2 HFS, the HFS-14 score was significantly higher in patients involving both the hands and the feet than in patients having only the hands or the feet severely affected; while Skindex-16, DLQI and SF-12 scores have no difference between these two groups.
Conclusions
The incidence of HFS induced by the treatment of anti-PD-1 antibody SHR-1210 combined with apatinib is extremely high. HFS-14 may serve as a more sensitive and valuable tool for early measuring HFS-related QoL impairment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract